// App-Quantinova.ai

P1095 : TREATMENT ATTRIBUTES FOR 3RD LINE FOLLICULAR LYMPHOMA TREATMENT DECISION-MAKING: PHYSICIAN PERSPECTIVES FROM A SURVEY ACROSS WESTERN EUROPE AND THE UNITED STATES

Researchers

Presenter

  • P. Connor Johnson

Principal Investigators

  • Abigail Bailey

  • Neil Milloy

  • Emily Clayton

  • Ruben G.W. Quek

  • Qiufei Ma

Medical Centers

  • Health Economics &amp

  • Oncology,Adelphi Real

  • Adelphi Real World,Bollington,Verenigd Koninkrijk

  • Department of Medicine, Division of Hematology &amp

  • Oncology,Massachusetts General Hospital Cancer Center &amp

  • Outcomes Research,Regeneron Pharmaceuticals Inc.,Sleepy Hollow,Stati Uniti

  • Adelphi Real World,Bollington,Regno Unito

  • Adelphi Real World,Bollington,Regno Unito

  • Harvard Medical School,Boston,États-unis

  • Harvard Medical School,Boston,Vereinigte Staaten

  • Adelphi Real World,Bollington,Royaume-uni

  • Oncology,Ma

  • Adelphi Real World, Bollington, United Kingdom

  • Outcomes Research,Regeneron Pharmaceuticals Inc.,Sleepy Hollow,Stati Uniti

  • Outcomes Research,Regeneron Pharmaceuticals Inc.,Sleepy Hollow,Stati Uniti

  • Adelphi Real World,Bollington,Vereinigtes Königreich

  • Outcomes Research,Regeneron Pharmaceuticals Inc.,Sleepy Hollow,Stati Uniti

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved